MEDINA participates in the NOVA-VRE project to develop new therapies to combat antibiotic-resistant bacteria.
Read moreEl camino que recorre un compuesto bioactivo antes de convertirse en un medicamento seguro y eficaz es largo, complejo y altamente regulado. Antes de avanzar a las fases clínicas, todo candidato debe...
Read moreFundacion MEDINA reaffirms its commitment to transparency in the use of animals for biomedical research, a principle it embraced in 2022 when it joined the Transparency Agreement on Animal Research, p...
Read moreFundación MEDINA presenta en Boston m3DinAI, una Nueva Plataforma de Cribado de Fármacos Antitumorales
Read moreThe key project objective is to apply state-of-the-art methodologies to prospect the bioactivity potential of lignin – a natural, abundant and sustainable biopolymer component of lignocellulosic bio...
Read moreThis collaboration allows combining experience and resources for the discovery and development of new therapies.
Read moreFundación MEDINA, the Drugs for Neglected Diseases initiative (DNDi) and Institut Pasteur Korea have been awarded a grant of EUR 995,000 from “la Caixa” Health Research 2020 program to identify n...
Read moreFundación MEDINA participará en el proyecto europeo del programa H2020 TOPCAPI, para la generación de factorías microbianas donde producir fármacos avanzados. Así, MEDINA participará en desa...
Read moreThe symposium is organized jointly by the Medicinal Chemistry Section of the Swedish Pharmaceutical Society and ENABLE, one of the projects in the Innovative Medicines Initiative ND4BB in which MEDINA...
Read moreBLUEandGREEN will be a complementary transdisciplinary effort of the five partners that will contribute on raising CIIMAR's scientific and technological standards in biorefineries approach based on ma...
Read moreMEDINA will develop its first novel antibiotic in a new European consortium aimed at bringing innovative solutions to fight bacterial infectious diseases. Over 30 European universities and c...
Read more